GRI Bio, Inc. (GRI) company profile
Close on Nov 17, 2026Market cap $2.95MP/E –Yield –
About GRI Bio
Pharmaceutical Preparations, SIC 2834
GRI Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses. Its pipeline concentrates on inflammatory, fibrotic, and autoimmune disorders by regulating Natural Killer T (NKT) cell activity. The company's lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant NKT cells being developed to treat severe fibrotic lung diseases, primarily idiopathic pulmonary fibrosis. Its portfolio also includes GRI-0803, an oral activator of type 2 diverse NKT cells aimed at treating autoimmune conditions such as systemic lupus erythematosus, along with a proprietary compound library. Because its pipeline is in clinical and preclinical development stages, the company serves patient populations in clinical trials rather than commercial end customers.
The company operates without internal commercial manufacturing infrastructure, contracting with third-party manufacturers to supply product candidates for its research and clinical studies. Its clinical studies include multicenter and multinational trials. The company's headquarters are not stated in the text.
Summary of the business section of GRI Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GRI Bio, Inc.
- Headquarters
- La Jolla, CA
- Address
- 2223 Avenida De La Playa, Suite 208 92037
- Phone
- (619) 400-1171
- Website
- gribio.com
- Employees
- 4, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, San Francisco, California
Stock & identifiers
- Ticker
- GRI
- Former tickers
- VLON until Apr 21, 2023
- Exchange
- Nasdaq
- IPO date
- Feb 11, 2021
- Shares outstanding
- 2M, Aug 13, 2026
- Public float
- $1.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-28 reverse, Jan 26, 2026; 1-for-17 reverse, Feb 24, 2025; 1-for-13 reverse, Jun 18, 2024; 1-for-7 reverse, Jan 30, 2024; 1-for-30 reverse, Apr 24, 2023
- SEC CIK
- 1824293
- CUSIP
- 3622AW502
- ISIN
- US3622AW5029
- FIGI
- BBG00XZQMLV6
- Share class FIGI
- BBG00XZQMLW5
- EIN
- 82-4369909
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Walter Marc Hertz | Chief Executive Officer, Director | 385,510 |
| Leanne Kelly | Chief Financial Officer | 6,250 |
| Vipin Chaturvedi | Chief Scientific Officer | 172,189 |
| Roelof Rongen | Director | – |
| David Charles Baker | Director | 7,843 |
| David Leslie Szekeres | Director | – |
| Camilla V. Simpson | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| W. Marc Hertz, Ph.D. President and Chief Executive Officer | $575.90K | $274.74K | $158.37K | $18.21K | $1.03M | +66% |
| Leanne Kelly Chief Financial Officer | $384.30K | $109.99K | $76.86K | $13.58K | $584.72K | +25% |
| Vipin Kumar, Ph.D. Chief Scientific Officer | $384.30K | $109.99K | $76.86K | $7.94K | $579.09K | +38% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 11, 2021
- Securities offered
- 2,250,000
- Exchange
- Nasdaq
- First trading day
- Feb 10, 2021
- First-day close
- $7.52
- Lock-up ends (est.)
- Aug 9, 2021
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of January 30, 2026 we had four employees, of which three were full-time employees and one was part-time.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?